Navigation Links
Study Questions Safety of Pneumonia Treatment Guidelines
Date:1/20/2011

WEDNESDAY, Jan. 19 (HealthDay News) -- Intensive care patients who may be infected with strains of pneumonia that are resistant to many drugs may be more likely to die if current treatment guidelines are followed, a new study suggests.

The findings highlight the need to reassess the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA) guidelines, said the researchers.

Current guidelines call for immediate antibiotic treatment -- before culture results are known -- of patients at risk for multiple drug-resistant (MDR) infection. The guidelines state that patients should receive a regimen of three antibiotics: two drugs against so-called Gram-negative pathogens and one drug against methicillin-resistant Staphylococcus aureus, or MRSA. The logic in this approach is that at least one drug should be active against any likely infectious agent.

However, several studies conducted since the guidelines were released in 2005 have failed to show that dual Gram-negative therapy is better than treatment with a single drug, the researchers noted.

For their study, a team led by Dr. Daniel Kett, of the University of Miami Miller School of Medicine, enrolled 303 patients at risk for MDR pneumonia from four academic medical centers in the United States. Of those patients, 129 were treated according to the ATS/IDSA guidelines and 174 received a different treatment.

The rate of survival after 28 days was 65 percent in the guidelines-compliant group and 79 percent in the group that didn't adhere to the guidelines, the investigators found.

"Our results further question the need for combination Gram-negative empirical treatment for patients with pneumonia, even those who are severely ill and at risk of multi-drug resistant pathogens," the researchers wrote.

One expert was not surprised by the findings.

"Who gets pneumonia with resistant bacteria? It is a person in such weakened condition that they are vulnerable to pathogens that would otherwise be trivial," noted Dr. Bruce Hirsch, attending physician in the infectious diseases division at North Shore University Hospital in Manhasset, N.Y. "It is a person who has suffered multiple infections already and has been exposed to multiple courses of antibiotics. It is a person with structural lung abnormalities that prevent the lungs from recovering from infections."

According to Hirsch, the new study "demonstrates high mortality rates in patients given recommended antibiotics as well as individualized antibiotics. Even in this age of sophisticated and powerful medications, adherence to the best guidelines can fail us."

For their part, the study authors "recommend that the planned, revised ATS-IDSA guidelines be reassessed before widespread implementation. Since the most common reason for non-compliance was failure to use a secondary anti-Gram-negative drug, we suggest a comparison of regimens employing MRSA treatment and single versus dual Gram-negative coverage."

The study was published in the Jan. 19 online edition of The Lancet Infectious Diseases.

More information

The American Lung Association has more about pneumonia.

-- Robert Preidt

SOURCES: The Lancet Infectious Diseases, news release, Jan. 19, 2011; Bruce Hirsch, M.D., attending physician, infectious diseases division, North Shore University Hospital, Manhasset, N.Y.


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Nurses Long Shifts May Put Hospital Patients at Risk: Study
2. Organs From High-Risk Donors Often Shunned, Study Finds
3. 1 in 5 Cancer Survivors Suffers Chronic Pain, Study Finds
4. Pitt study: End-of-life decisions take longer if patient hasnt shared wishes with family
5. New Pediatrics study identifies the risks, consequences of video game addiction
6. Wayne State University study predicts risk of memory loss in healthy, older adults
7. One in 12 Fans Leaves Major Sports Events Drunk: Study
8. Damage of False-Positive Mammograms Overlooked: Study
9. Adult ADHD Often Precedes Certain Type of Dementia: Study
10. Study suggests possible new treatment for severe 2009 H1N1 infection
11. Problem Drinkers Marry Later, Break Up Sooner: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study Questions Safety of Pneumonia Treatment Guidelines
(Date:9/25/2017)... ... September 25, 2017 , ... G-CON Manufacturing, the ... and Modular (PCMM) collaboration with Pfizer and GEA by designing and building additional ... new PODs will provide tablet coating capability in the existing line at Pfizer’s ...
(Date:9/25/2017)... , ... September 25, 2017 , ... PITTSBURGH...An inventor, from ... update patient charts in hospitals and medical facilities, so he invented the COMPLETE PATIENT ... update patient charts. In doing so, it offers an improved alternative to paper charts ...
(Date:9/25/2017)... , ... September 25, 2017 , ... ... improve quality and efficiency. The principle of First-Defect-Stop for laboratory weighing ... before they have the chance to have negative consequences on downstream processes. , ...
(Date:9/25/2017)... , ... September 25, 2017 , ... METTLER TOLEDO is ... October 25-26, 2017 in Los Angeles, CA. The symposium will feature speakers from North ... with today's mass calibration technologies and help with planning for the future of the ...
(Date:9/25/2017)... ... 2017 , ... The Asset Tracking and Temperature monitoring system works in conjunction ... the bar code of the product and lot ID then scanning the HPP basket ... are automatically generated and exception alerts sent out to designated individuals. , "In recognizing ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that ... developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and ...
(Date:9/13/2017)... --  OrthoAtlanta has been named the official orthopedic and ... for the 2018 College Football Playoff (CFP) National Championship to ... in Atlanta, Georgia . OrthoAtlanta is proud ... participating in many activities leading up to, and including the ... ...
Breaking Medicine Technology: